Mobile website
Archive > Volume 23 Issue 6 > 2016,23(6):819-823. DOI:10.3872/j.issn.1007-385X.2016.06.014 Prev Next
Clinical Research
Retrospective study on autologous DC-CIK cell combined with chemotherapy for the patients with advanced gastric cancer
- Article
- Figures
- Metrics
- Preview PDF
- Reference
- Related
- Cited by
- Materials
Abstract:
Objective:To retrospectively evaluatethe efficacy, quality of life and safety of autologous DC-CIK cells in patients with advanced gastric cancer. Methods: Seventy patientswith advanced gastric cancer who received autologous DC-CIK immunotherapy plus chemotherapy, defined as combination group, were analyzed. Another seventy gastric cancer patients with similar clinical characteristics and received chemotherapy alone, defined as control group,were also selected. The response rate, survival, quality of life and toxicities were respectively analyzed for two groups. Results: In combination group and control group, the response rate was 37.8% versus 29.5% (P>0.05), disease control rate 80.0% versus 59.1% (P<0.05), progression-free survival 7.0 months versus 5.0 months (HR 0.62,95%CI 0.41-0.92, P<0.05) and overall survival 13.0 months versus 10.8 months (HR 0.68,95%CI 0.45-1.02, P>0.05). Compared to that in control group, the quality of life did not decrease obviously after chemotheray in combination group. No severe toxicity was observed after infusion of DC-CIK cells. Conclusion: DC-CIK immunotherapy in combination with chemotherapy demonstrated some clinical benefits, and no severe toxicity appeared in patients with advanced gastric cancer.
Keywords:
Project Supported:
Project supported by the Natural Science Foundation of Gansu Province (No.145RJZA036)
Clc Number:
